Medical cannabis advertising in South Africa is tightly restricted by two separate laws at once. Under the Cannabis for Private Purposes Act 7 of 2024, advertising cannabis for sale falls inside the legal definition of “dealing”, an offence carrying up to 10 years unless the activity is authorised. Under the Medicines and Related Substances Act 101 of 1965, no medicine or Scheduled substance may be advertised for sale except as prescribed, and false or misleading claims are separately criminalised.
Last updated:
Key takeaways
- Two statutes apply simultaneously. Cannabis law treats advertising for sale as dealing. Medicines law governs how any medicine may be advertised at all.
- The legal definition of “advertisement” is deliberately wide: anything brought to the notice of the public in any manner whatsoever, if it is intended to promote a sale. A social post, a listing or an influencer mention can qualify.
- Products supplied under a SAHPRA Section 21 authorisation are by definition unregistered, so no efficacy has been stated by the regulator for anyone to advertise.
- For patients, this is the practical consequence: you will not find legitimate access through adverts. Compliant operators say less, not more, so a loud advert is a warning sign rather than a recommendation.
- Nothing here is legal advice. Operators should take advice on their own facts, and this page does not tell anyone how to get around a restriction.
If you arrived here as a patient rather than a marketer, the short version is that adverts are not the route. Register for Professor Green store access to create an account and start the process properly.
What counts as medical cannabis advertising in South African law
Most compliance mistakes here begin with an assumption that “advertising” means paid media. The Medicines and Related Substances Act 101 of 1965 defines it far more broadly. An advertisement, in relation to any medicine or Scheduled substance, is any written, pictorial, visual or other descriptive matter or verbal statement appearing in a newspaper, magazine, pamphlet, electronic media including radio and television, or other publication; or distributed to members of the public; or brought to the notice of members of the public in any manner whatsoever, where it is intended to promote the sale of that medicine or substance.
Three things follow from that wording. The medium does not matter, so a website page, a social post, a WhatsApp broadcast and a printed flyer all sit inside the definition. Payment does not matter, so unpaid organic content and a creator posting on your behalf are not outside it. What matters is the intention to promote a sale.
The same Act reinforces this in its definition of “sell”, which expressly includes to advertise. In other words, advertising is not a separate activity that sits alongside selling. In medicines law it is treated as part of selling, which is why an advertising decision can carry the same consequences as a supply decision.
The two statutes that govern medical cannabis advertising
The reason medical cannabis advertising is harder than ordinary healthcare marketing is that two regimes apply to the same message at the same time, and complying with one does not discharge the other.
| Cannabis for Private Purposes Act 7 of 2024 | Medicines and Related Substances Act 101 of 1965 |
|---|---|
| “Deal in” expressly includes “advertise for sale”, alongside selling, buying, offering for sale and importing. | Section 18(2): no person may advertise any medicine or Scheduled substance for sale unless the advertisement complies with the prescribed requirements. |
| Section 4(1): dealing in cannabis is an offence, on conviction a fine or up to 10 years imprisonment, or both. | Section 20(1)(a): no false or misleading advertisement concerning any medicine may be published or distributed. |
| The offence does not apply to activity expressly authorised by that Act, or under a permit or licence issued under other national legislation. | Section 20(1)(b): no claim that a medicine’s therapeutic efficacy differs from what the Authority has stated, and no suggestion of use for a purpose or in a manner other than as stated. |
| A child is anyone under 18, and the Act separately prohibits engaging a child to deal in cannabis. | Section 18C: the Minister makes regulations on marketing, including Codes of Practice for the relevant industries. |
The authorisation carve out in the cannabis Act is the pivot point, and it is narrower than operators often hope. It protects activity that is expressly authorised, or carried on under a permit or licence issued under other national legislation. A licensed activity does not license a message that goes beyond it, which is where the medicines Act takes over.
The Section 21 problem nobody plans for
Much of the medical cannabis supplied in South Africa moves under a Section 21 authorisation, where the regulator permits a named patient to receive an unregistered medicine on a prescriber’s application. That mechanism creates a specific advertising trap.
Section 20(1)(b) of the Medicines Act prohibits claiming a therapeutic efficacy other than that stated by the Authority. For an unregistered product, the Authority has not evaluated and stated an efficacy at all. There is therefore no approved claim available to repeat, and any efficacy claim made in public about such a product is being made without the foundation the section assumes. This is the structural reason compliant operators speak about process and access rather than outcomes. If you want the mechanics of that authorisation route, we set them out in our walkthrough of SAHPRA Section 21, step by step.
Before you start
This page is general information for adults 18 and over, not legal or medical advice, and it is not a route around any restriction. In South Africa, medical cannabis containing THC is prescription only through a registered doctor, usually via a SAHPRA Section 21 authorisation. Operators should take their own legal advice on their specific licences and messaging. Patients should speak to a doctor or pharmacist before starting, stopping or changing any treatment, including anything about dosing.
What compliant operators do instead
The practical answer to medical cannabis advertising restrictions is not a cleverer advert. It is a shift of effort away from promotion and towards material that is useful whether or not anyone buys anything.
Educational content about the law, the access process and what a consultation involves is not primarily intended to promote the sale of a specific medicine, which is the hinge the statutory definition turns on. Explaining what a Section 21 application is, who applies for it and how long it takes, informs a reader without making a product claim. Publishing clear pricing structures, service descriptions and qualifications does the same.
Where evidence is discussed at all, it belongs to the cannabinoid research literature, attributed and dated, and firmly separated from any claim about a specific product on sale. Our page on medical cannabis for chronic pain in South Africa is written that way deliberately: it reports what the research reviews concluded, including where the evidence is weak, rather than promising a result.
Three habits do most of the work. Describe the process rather than the product. Attribute every clinical statement to a named source rather than asserting it. Say plainly what you do not do, because the boundaries of a service are exactly what a regulator, and a cautious patient, want to see stated.
Researching medical cannabis advertising because you are trying to find legitimate access rather than run a campaign? The compliant route starts with an account, not an advert. Create your Professor Green account and take the next step with a prescriber.
How Professor Green fits into the process
Professor Green is a South African medical cannabis platform. Registering creates your account and opens the member and store area, which is where the access journey begins. That is the whole of what registration itself does.
Professor Green does not diagnose, does not prescribe, does not decide clinical suitability, does not dispense and does not grant a Section 21 authorisation. Those acts belong to other authorised parties. A registered doctor assesses the patient, writes any prescription and makes the Section 21 application to SAHPRA where an unregistered product is involved. A licensed pharmacy dispenses. Delivery or collection of a dispensed medicine is handled under those arrangements. Registration does not guarantee eligibility, a prescription, approval, stock or supply.
Stating that plainly is itself part of complying with the rules described above. A platform that implied it could deliver a clinical outcome would be making exactly the kind of claim section 20 exists to prevent.
How patients should read what they see
Because the restrictions bite hardest on the most compliant operators, the advertising landscape is inverted. The businesses working inside the law are the quietest, and the loudest offers are frequently the ones with the least to lose. That makes marketing volume a poor signal of legitimacy and a reasonable warning sign.
Some patterns are worth treating as red flags: a guaranteed result or a promise that a condition will be cured or reversed; an offer of THC products with no prescriber involved anywhere in the process; pressure to buy immediately; testimonials presented as evidence of a clinical outcome; and any suggestion that a prescription or Section 21 authorisation is a formality that can be arranged for you. Our guide to what a dispensary legally is, and how to check one covers the verification steps in more detail.
The healthier signals are unglamorous. A named prescriber, a clear explanation of the legal route, a licensed dispensing arrangement, an explicit statement of what the service does not do, and a willingness to say that the evidence for a given use is limited. None of that reads like an advert, which is rather the point.
Frequently asked questions about medical cannabis advertising
Is medical cannabis advertising legal in South Africa? Only within narrow limits. Advertising cannabis for sale falls within the definition of dealing under the Cannabis for Private Purposes Act 7 of 2024, which is an offence unless the activity is authorised under that Act or under a permit or licence issued under other national legislation. Separately, the Medicines and Related Substances Act 101 of 1965 provides that no medicine or Scheduled substance may be advertised for sale unless the advertisement complies with the prescribed requirements.
Does a social media post count as an advertisement? It can. The Medicines Act defines an advertisement as descriptive matter or a statement brought to the notice of members of the public in any manner whatsoever, where it is intended to promote a sale. The definition is not limited to paid media, so organic posts and content published by a third party on a business’s behalf can fall inside it.
What penalty applies to advertising cannabis for sale? Because advertising for sale is included in the definition of dealing, section 4(1) of the Cannabis for Private Purposes Act 7 of 2024 applies. A person who deals in cannabis is guilty of an offence and liable on conviction to a fine or imprisonment for a period not exceeding 10 years, or both.
Can a licence make cannabis advertising lawful? The cannabis Act’s offence does not apply to activity expressly authorised by that Act, or in terms of a permit or licence issued under other national legislation. That carve out is tied to the authorised activity itself. It does not exempt a business from the separate advertising requirements in the Medicines and Related Substances Act, which apply to the message.
Why can compliant clinics not advertise results? Section 20(1)(b) of the Medicines Act prohibits claiming a therapeutic efficacy other than that stated by the Authority. Where a product is supplied as an unregistered medicine under a Section 21 authorisation, the regulator has not evaluated and stated an efficacy, so there is no approved claim available to advertise.
Are testimonials allowed? A testimonial that presents a clinical outcome functions as an efficacy claim, and it carries the same risk under sections 20(1)(a) and 20(1)(b) as any other claim. It cannot substitute for an efficacy stated by the regulator, and if it is misleading it engages the false advertising prohibition directly.
May cannabis marketing be directed at young people? No. The Cannabis for Private Purposes Act 7 of 2024 defines a child as a person under 18 and prohibits supplying cannabis to a child or engaging a child to deal in cannabis. Any content, imagery or placement that targets or appeals to under 18s is incompatible with that framework.
Is this page legal advice for operators? No. It summarises the statutory provisions and links to the primary sources so they can be read directly. Application depends on the specific licences, products and wording involved, and operators should take their own legal advice on their facts.
The honest summary
Medical cannabis advertising in South Africa is governed by a cannabis statute that treats promotion as dealing and a medicines statute that controls what may be said about any medicine at all. Read together, they leave very little room for product promotion and a great deal of room for genuine explanation. For operators that means competing on clarity rather than reach. For patients it means the opposite of the usual instinct: the quiet, specific, carefully hedged source is more likely to be the lawful one than the confident advert.
Sources and references
- Cannabis for Private Purposes Act 7 of 2024 (Government Gazette 50744, 3 June 2024), for the definitions of “deal in” and “child”, the section 4(1) offence and penalty, and the authorisation carve out.
- Medicines and Related Substances Act 101 of 1965, for the definitions of “advertisement” and “sell”, section 18(2) on advertising, section 18C on marketing regulations and Codes of Practice, and section 20 on false or misleading advertisements.
- SAHPRA, Section 21 access to unregistered medicines, for the named patient authorisation route referred to throughout.
- Constitutional Court, Minister of Justice and Constitutional Development v Prince (2018), for the private adult use position that is distinct from any commercial or medical activity.
The legitimate route is not an advert
Because medical cannabis advertising is restricted, patients find lawful access through a registered platform and a prescriber, not through promotions. Registering creates your Professor Green account and opens the store area. It is a first step, not a guarantee of eligibility or supply.
Register for Professor Green Store Access

